Over 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.
Approved by the U.S. Food and Drug Administration (FDA) in ...
continue reading...
Janssen Pharmaceuticals and Bayer have long insisted their blood-thinning drug Xarelto is a safer, more reliable alternative to the decades-old warfarin. However, a new study recently published in the American Heart Association’s journal Circulation suggests the popular “new-age” anticoagulant may be no safer than warfarin in terms of bleeding in elderly patients.
Xarelto was approved by the U.S. Food and Drug Administration in 2011 ...
continue reading...
Amid recent research linking sodium-glucose cotransporter-2 (SGLT2) inhibitors to diabetic ketoacidosis, Invokana maker Janssen Pharmaceutica has countered with its own report on the new diabetic drug. The study, published in late July by the journal Diabetes Care, claims that incidents of the potentially fatal blood condition are “rare.”
SGLT2 inhibitors are a relatively new class of type 2 diabetes drugs. They work by reducing the amount of glucose reabsorbed in the ...
continue reading...
While sodium-glucose cotransporter-2 (SGLT2) inhibitors draw praise for their weight-loss and blood pressure reduction benefits, medical experts continue to puzzle over their more immediate metabolic and immune system effects. Specifically, researchers are worried about their possible link to diabetic ketoacidosis, a potentially fatal condition caused by excess blood acids, or ketones. In an article published by the Journal of Diabetes Investigation, two Japanese researchers provide a possible explanation for how
continue reading...
A Wisconsin woman has filed a Xarelto lawsuit against multiple pharmaceutical companies for damages allegedly resulting from the anticoagulant drug. The plaintiff states that the defendants, including Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals, did not adequately warn doctors and patients of the risk of uncontrollable bleeding that Xarelto poses. The Xarelto lawsuit further claims that the drug’s manufacturers failed to provide appropriate instructions on how to intervene should serious ...
Johnson & Johnson Chairman and Chief Executive Alex Gorsky’s total pay rose 48 percent in 2014, an article from the Wall Street Journal Reports. Board members say they made the decision based on Johnson & Johnson’s success in achieving short- and long-term financial goals and building on the momentum of its pharmaceutical business.
Despite these positive reviews, 2014 was a year fraught with ...
continue reading...
